Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

Clinical trial NCT07488884 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07488884
Sponsor: ImmunityBio, Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Pancreatic Cancer Resectable Pancreatic Cancer

Start date: 2026-06-01
Primary completion: 2027-06-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.